Sofdra growth drives Botanix Q4 FY26 update, record June shipments
Botanix Pharmaceuticals reports accelerating Sofdra adoption in Q4 FY26, with prescriptions up 25% to 33,358 and a June monthly peak of 12,895, alongside $46.7 million in gross sales and a $10.1 million net revenue, aided by a improving gross-to-net yield of 22%. The company is trimming costs, expanding its API supplier base, fortifying its IP position, and narrowing operating cash burn as it strengthens its US market focus and dual US-Australia business footprint to support sustainable growth.
Business · 5 sources · Jul 27, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Bone Medical
Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company's lead product is Sofdra, which treats axillary hyperhidrosis. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex, for direct skin delivery of active pharmaceuticals which is utilised in all of their programs.
Everything about Bone Medical →- Country
- Australia
- Headquarters
- Perth
- Inception
- 2002
- Website
- http://www.bone-ltd.com/